Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-03-07
2006-03-07
Wilson, James O. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
Reexamination Certificate
active
07008931
ABSTRACT:
The invention concerns the use for preparing a medicine for treating inflammatory diseases induced by non-specific inflammatory responses, that is antigen-independent, of a laminarin sulphate, having a degree of sulphation not less than 1.9 and preferably between 2 and 2.5 degree of polymerization identical to that of the natural molecule, that is 20 to 30.
REFERENCES:
patent: 3200110 (1965-08-01), Gollin et al.
patent: 5135920 (1992-08-01), Kanamaru et al.
patent: 6190875 (2001-02-01), Ben-Artzi et al.
patent: 49130478 (1974-12-01), None
patent: WO 95/24907 (1995-09-01), None
Vlodavsky et al. “Inhibition of tumor metastasis by heparanase inhibiting species of heparin,” Invasion Metastasis, 1994-95, vol. 14, pp. 290-302.
Hershkoviz et al. “Differential effects of polysulfated polysaccharide on experimental encephalomyelitis, proliferation of autoimmune T cells, and inhibition of heparanase activity,” Journal of autoimmunity (1995) vol. 8, pp. 741-750.
Bohn, J.A. et al., “(1-3)-β-D-Glucans as Biological Response modifiers: a review of structure-functional activity relationships”,Carbohydr. Polym.(1995), vol. 28, pp. 3-14.
Cirellis, Al. F. et al., “Effect of sulfation on the biological activity of β-(1-3)-glucans from the tree fungusCyttańa hariotiFischer”, Carbohydr. Res., vol. 190, (1989), pp. 329-337.
Paper D H, “Natural Products As Angiogenesis Inhibitors”,Planta Medica, 1998, Vol. 64, No. 8, pp. 686-695 (XP002176352).
Hoffman R et al., “Inhibition of Angiogenesis and Murine Tumour Growth by Laminarin Sulphate”,British Journal of Cancer;1996, vol. 73, No. 10, pp. 1183-1186.
Yoshido, Tomoaki et al, “A Liquid-Phase Binding Analysis for L-Selectin”,Eur. J. Biochem, 1994, vol. 222(2), pp. 703-709 (XP001016234).
Xie X et al., “Inhibition of Selectin-Mediated Cell Adhesion and Prevention of Acute Inflammation by Monanticoagulant Sulfated Saccharides Studies With Carboxy-Reduced and Sulfated Heparin and With Trestatin A Sulfate”,J. Biological Chemistry, American Society of Biological Chemists, 2000, Vo. 275, No. 44, pp. 34818-34825 (XP001031395).
Suzuki, et al., “Preparation and Biological Activities of Sulphated Derivatives of (1.fwdarw. 3)- .beta- D-Glucans”,J. Pharmacobio-Dyn., 1991, vol. 14(5), pp. 256-266.
Database CA., “Polysaccharide Sulfuric Acid Esters”,Chemical Abstracts Service, Columbus, Ohio, retrieved from STN Database Accession No. 83:12692 XP002176355 & JP 49 130478 A (Ajinomoto Co., Inc.) Dec. 13, 1974.
Database CA, “Veterinary-Clincal Uses of Curdian Sulfate”,Chemical Abstracts Service, Columbus, Ohio, retrieved from STN Database Accession No. 132:73593 XP002176356 A (Kichin, Kitosan Kenkyu) 1999, pp. 166-167.
Database Phin, “Goemar Expects French Approval for GL 32”,Agrow Newsletter, 2000, No. 352, p. 22 (XP002176357).
Alban Susanne
Franz Gerhard
Yvin Jean-Claude
Johnsen Jason H.
Laboratoires GOEMAR S.A.
McDonnell Boehnen & Hulbert & Berghoff LLP
Wilson James O.
LandOfFree
Anti-inflammatory and healing medicine based on laminarin... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-inflammatory and healing medicine based on laminarin..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-inflammatory and healing medicine based on laminarin... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3564807